pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Nereus
drug
save

tradipitant

Marketedupdated 6mo ago
by $VNDA Vanda Pharmaceuticals Inc.
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • tagApproval4 co-mentions · 1 sources
  • tagSmall Molecule2 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying tradipitant

  • phase3Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesiscompletedn=979
  • phase3A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Userecruitingn=280
  • phase3Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sicknessactive not recruitingn=705
  • phase2A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Usecompletedn=124
  • —Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesisavailable
  • phase2Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sicknesscompletedn=126
  • phase3Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sicknesscompletedn=316
  • phase3Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesisrecruitingn=100

Patent cliff

source: FDA Orange Book
first barrier falls
Dec 30, 2030
~4.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

  • Aug 9, 2036method-of-use (U-4396)US 12318375
  • Mar 4, 2036method-of-use (U-4396)US 10772880
  • Mar 4, 2036method-of-use (U-4396)US 10821099
  • Mar 4, 2036method-of-use (U-4396)US 11324735

FDA exclusivities (1)

  • Dec 30, 2030NCENew Chemical Entity (5y)4.1y

News(1)

  • Vanda freezes Novartis-originated social anxiety program after late-stage disappointment
    While Oppenheimer doesn’t see the Phase 3 stumble of VQW-765 as highly detrimental to Vanda Pharmaceuticals, the analyst nevertheless believes the stakes are now higher for the company’s planned Q4…
    biospace · 1mo ago
brand
Nereus
generic
tradipitant
indication
Motion Sickness
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?